Welcome to our dedicated page for Viemed Healthcare SEC filings (Ticker: VMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Viemed Healthcare, Inc. (VMD) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures, along with AI-generated summaries to help interpret complex documents. Viemed is incorporated in British Columbia, Canada and files with the SEC under Commission File Number 001-38973, with its common shares listed on NASDAQ under the symbol VMD.
For a company operating as an in-home clinical care provider of post-acute respiratory healthcare equipment and services in the United States, core filings such as the annual report on Form 10-K and quarterly reports on Form 10-Q are central resources. These documents typically contain detailed information on revenue from respiratory equipment and services, operating expenses, cash flows, and risk factors relevant to its non-invasive ventilation, sleep therapy, oxygen therapy, staffing, and related activities.
Viemed also files frequent current reports on Form 8-K to disclose material events. Recent 8-K filings have covered quarterly and year-to-date financial results, the completion of a share repurchase program, the acquisition of Lehan’s Medical Equipment, and amendments to the company’s credit agreement that extend certain term loan commitment expiration dates and provide technical changes. Some 8-K filings also furnish investor presentations and financial supplements used in communications with analysts and investors.
On this page, users can review Form 4 and other insider transaction filings, where available, alongside periodic and current reports. Stock Titan’s AI tools summarize lengthy filings, highlight key sections, and surface items such as changes to credit facilities, capital allocation actions, and updates to financial guidance that Viemed has chosen to disclose. Real-time updates from EDGAR ensure that new Viemed filings appear promptly, while AI-generated insights are designed to make the company’s regulatory record more accessible to both experienced and newer investors.
Viemed Healthcare, Inc. insider William Todd Zehnder, the Chief Operating Officer and a director, reported equity compensation transactions on
To cover related tax obligations from the RSU vesting, the company withheld 35,075 common shares at a per‑share value of
After these transactions, Zehnder directly owned 374,835 common shares, along with 235,094 RSUs and 17,107 phantom share units that remain outstanding and continue to represent future or cash‑settled economic exposure to Viemed common shares.
Viemed Healthcare Chief Financial Officer Fitzgerald Trae reported equity award activity involving restricted stock units, phantom share units, and common shares on January 21, 2026. A block of 13,317 restricted stock units vested and converted into common shares, with 4,246 of those shares withheld by the company to cover taxes at a per-share value of $7.49, leaving 98,523 common shares directly held after the transactions. In addition, 3,329 cash-settled phantom share units vested under the company’s Phantom Share Unit Plan, which were economically equivalent to common shares and were settled in cash through a matched acquisition and disposition of 3,329 underlying common shares. Following these events, Trae held 26,632 restricted stock units and 6,658 phantom share units, each unit tied to one common share.
Viemed Healthcare Vice President of Sales Cambre Jerome reported equity award activity and related share transactions. On January 21, 2026, 11,719 Restricted Stock Units (RSUs) vested and were settled into an equal number of common shares, consistent with each RSU representing one common share. To cover taxes from this vesting, the issuer withheld 3,827 common shares at a per-share value of $7.49, based on the market closing price for that date.
The filing also shows vesting of 2,930 cash-settled phantom share units granted under Viemed’s Phantom Share Unit Plan, which are economically equivalent to common shares. The settlement is reported as an exchange of phantom shares for the underlying common shares and a simultaneous disposition of those common shares back to the company for cash. After these transactions, Jerome directly beneficially owned 97,824 common shares, as well as 23,436 RSUs and 5,859 phantom share units that remain outstanding.
Viemed Healthcare General Counsel Jeremy Trahan reported multiple equity-related transactions on January 21, 2026. He exercised and vested 14,648 Restricted Stock Units, each converting into one common share, bringing his directly held common shares at one point to 43,440.
To cover taxes from the RSU vesting, the company withheld 4,783 common shares at a per-share value of $7.49, leaving Trahan with 38,657 common shares after that step. He also had 3,662 cash-settled phantom share units vest under the Phantom Share Unit Plan, economically equivalent to common shares, with settlement reported as both acquisition and disposition of the related common shares.
Following these transactions, Trahan held 29,296 Restricted Stock Units and 7,324 phantom share units, both scheduled to vest in equal annual installments through January 21, 2028, aligning a portion of his compensation with Viemed Healthcare’s share performance over time.
Viemed Healthcare CEO Hoyt Casey reported multiple equity transactions. On January 17, 2026, previously granted awards vested, resulting in the acquisition of 40,068 common shares and 10,017 common shares tied to phantom share vesting. To cover tax obligations and settle cash awards, 12,118 shares were withheld by the company and 10,017 shares were disposed of at $7.33 per share.
Following these transactions, Casey directly held 288,550 common shares and also reported indirect beneficial ownership of 1,984,943 common shares held by Elizabeth Rose Homes LLC. On January 19, 2026, he received new grants of 172,155 restricted stock units and 43,039 phantom share units, each representing the value of one common share and scheduled to vest in three equal annual installments beginning one year after the grant dates.
Viemed Healthcare, Inc. reported an insider equity award for Chief Medical Officer and director William Frazier. On January 19, 2026, he received 11,690 Restricted Stock Units (RSUs), each representing a contingent right to one common share. These RSUs vest in three equal annual installments beginning on the first anniversary of the grant date.
On the same date, he was also granted 2,922 Phantom Share Units under the company’s Phantom Share Unit Plan. Each phantom share represents the right to receive the cash value of one common share, determined based on the share price on the vesting date, and also vests in three equal annual installments starting one year after the grant date.
Viemed Healthcare President Michael Moore reported equity compensation and related share settlements. On January 19, 2026, he received 118,759 Restricted Stock Units and 29,690 phantom share units, each representing the value of one common share and vesting in three equal annual installments beginning on the first anniversary of the grant date. Earlier, on January 17, 2026, previously granted RSUs and phantom units vested, resulting in the acquisition and disposition of matching common shares, including 8,548 shares withheld at $7.33 per share to cover taxes. After these transactions, Moore directly beneficially owned 144,734 common shares and indirectly owned 1,722,614 common shares through Moore Faster LLC.
Viemed Healthcare, Inc. reported insider equity activity for Chief Operating Officer and director William Todd Zehnder. On January 19, 2026, he received 118,759 Restricted Stock Units (RSUs) and 29,690 phantom share units, each tied to one common share or its cash value and vesting in three equal annual installments beginning one year after the grant date.
On January 17, 2026, previously granted awards from January 17, 2023 partially vested. This led to the acquisition of 26,939 common shares from RSUs and 6,735 common shares tied to cash-settled phantom shares, followed by dispositions back to the company. The filing also shows 8,550 common shares withheld at $7.33 per share to cover taxes. After these transactions, Zehnder directly held 292,362 common shares, plus the new RSU and phantom unit balances.
Viemed Healthcare vice president of sales Jerome Cambre reported equity compensation and related tax transactions in company stock. On
On
Viemed Healthcare (VMD) Chief Financial Officer Trae Fitzgerald reported a mix of equity awards vesting, tax withholding, and new grants. On January 17, 2026, 9,590 restricted stock units and 2,397 cash-settled phantom share units vested, each unit economically equal to one common share. To cover taxes from RSU vesting, 3,132 common shares were withheld at $7.33 per share, based on the January 16, 2026 closing price, and 2,397 common shares were delivered back to the company in connection with phantom share settlement. After these transactions, Fitzgerald directly held 89,452 common shares.
On January 19, 2026, Fitzgerald received new equity awards of 46,662 restricted stock units and 11,666 phantom share units, each with a stated value of $0 per unit on grant and scheduled to vest in three equal annual installments beginning on the first anniversary of the grant date.